Cim Investment Management Inc Metacrine, Inc. Transaction History

Cim Investment Management Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 17, 2022	SELL	$0.43 - $0.7 $8,193 - $13,337	-19,054 Closed	0 $0
Q4 2021 May 19, 2022	SELL	$0.64 - $3.83 $12,194 - $72,976	-19,054 Reduced 50.0%	19,054 $13,000
Q4 2021 Feb 02, 2022	BUY	$0.64 - $3.83 $12,194 - $72,976	19,054 Added 100.0%	38,108 $78,000
Q1 2021 May 20, 2021	BUY	$6.2 - $11.0 $118,134 - $209,594	19,054 New	19,054 $118,000

Ticker MTCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,569,500
Description
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Get notified when there are updates to the investment portfolio of Cim Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Cim Investment Management Inc with notifications on news.